Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Nkarta Inc
(NQ:
NKTX
)
5.320
-0.110 (-2.03%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Nkarta Inc
Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
August 13, 2024
From
Nkarta, Inc.
Via
GlobeNewswire
Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights
August 13, 2024
From
Nkarta, Inc.
Via
GlobeNewswire
Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President
July 16, 2024
From
Nkarta, Inc.
Via
GlobeNewswire
Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications
June 27, 2024
From
Nkarta, Inc.
Via
GlobeNewswire
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
May 09, 2024
From
Nkarta, Inc.
Via
GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
April 08, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
April 05, 2024
From
Law Offices of Howard G. Smith
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors
April 05, 2024
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Nkarta Announces Pricing of $240 Million Underwritten Offering
March 25, 2024
From
Nkarta, Inc.
Via
GlobeNewswire
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
January 09, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:AMGN),(NASDAQ:AMAM),(NASDAQ:ELEV),(NASDAQ:NKTX) EQNX::TICKER_END
Via
FinancialNewsMedia
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
January 09, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition
December 09, 2023
From
Nkarta, Inc.
Via
GlobeNewswire
Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights
November 09, 2023
From
Nkarta, Inc.
Via
GlobeNewswire
Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis
October 17, 2023
From
Nkarta, Inc.
Via
GlobeNewswire
Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures
October 16, 2023
Call scheduled for Tuesday, October 17, 2023 at 8:00 a.m. ET
From
Nkarta, Inc.
Via
GlobeNewswire
Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights
August 10, 2023
From
Nkarta, Inc.
Via
GlobeNewswire
Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia
June 27, 2023
From
Nkarta, Inc.
Via
GlobeNewswire
Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program
June 26, 2023
Call scheduled for Tuesday, June 27, 2023 at 8:00 a.m. ET
From
Nkarta, Inc.
Via
GlobeNewswire
Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma
June 10, 2023
From
Nkarta, Inc.
Via
GlobeNewswire
Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights
May 11, 2023
From
Nkarta, Inc.
Via
GlobeNewswire
Nkarta Presents Preclinical Data Exploring Gene Knockout Strategies and Combination Agents with NK Cell-Based Therapies at the 2023 AACR Annual Meeting
April 17, 2023
From
Nkarta, Inc.
Via
GlobeNewswire
Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
March 16, 2023
From
Nkarta, Inc.
Via
GlobeNewswire
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
December 06, 2022
Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds.
Via
TheNewswire.com
Nkarta Announces Updated Clinical Data on Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 for Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
December 05, 2022
From
Nkarta, Inc.
Via
GlobeNewswire
Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights
November 09, 2022
From
Nkarta, Inc.
Via
GlobeNewswire
Nkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies and Next Generation Commercial-Scale Manufacturing Platform at SITC 37th Annual Meeting
November 07, 2022
From
Nkarta, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.